June 10, 2016
Takeda Pharmaceutical is aiming to become a top 10 company in the global oncology market in 2025 by capitalizing on two hoped-to-be-blockbusters for blood cancer - Ninlaro (ixazomib) and Adcetris (brentuximab vedotin). The target was revealed by Christophe Bianchi, president...read more